SUZHOU, China--(BUSINESS WIRE)--BioBay Investor Forum 2011 concluded a successful meeting, after selecting Chiva Pharmaceuticals, Inc. and Suzhou Biologix Medical Technology as the two “Most Promising” of the presenting companies. The event brought together more than 240 investors, entrepreneurs and industry experts to hear presentations from 19 of China's young life science companies. The event, held September 21-22, was the fourth annual holding of the BioBay Forum. It was organized by ChinaBio® LLC and Suzhou BioBay Life Science Park.
The 19 companies, which were drawn from the device, biotechnology, diagnostic, and services sectors, are developing novel technologies to address unmet needs in China and the world.
For the first time, this year’s event featured a panel of judges composed of influential life science investors and executives giving each company immediate feedback following their presentations. The reactions provided companies with valuable insight into their business plans, while attendees learned valuable tips on how to provide information that prospective investors or partners may find compelling.
Chiva Pharmaceuticals is a US and China-based pharmaceutical company that is in-licensing clinical and pre-clinical stage novel molecules to be developed for the Chinese and global markets. Chiva’s goal is to become a leading pharmaceutical company in China that competes on the world stage. Dr. David Xi, President and CEO, received his PhD in biochemistry from Rice University and worked at Gilead prior to founding Chiva.
Suzhou Biologix is an early stage medical diagnostics company developing ultra-portable devices for point-of-care (POC) and telemedicine. Their first product is a vital signs remote monitoring system that utilizes a “band-aid” sized sensor system that enables remote monitoring through cloud computing. This will be the first product of its type in the Chinese market. Suzhou Biologix was founded by Dr. Lei Chen, a board-certified pathologist, who received his medical degree from Hunan Medical University and PhD from University of Alabama at Birmingham.
“This year’s BioBay Forum continued to raise the bar for the quality of our events,” said Greg Scott, CEO of ChinaBio® LLC. “The level of interest among the VCs and potential partners was very high, and everybody at the Forum felt the excitement. The 19 presenting companies were very high quality, validating China’s ability to create innovative technologies in the life science sector,” he concluded.
“The annual BioBay Investor Forum is always a highpoint on our yearly schedule,” said Yuwen Liu, Chairwoman and CEO of BioBay Park. “This year’s event was a great success with excellent presenting companies and strong attendance from the VC community. All the attendees took full advantage of the event’s networking opportunities and expressed interest in returning next year,” she concluded.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio® LLC has rapidly created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped global life science companies identify over 400 licensing and acquisition opportunities in China and China companies raise nearly $450 million.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Capital: ChinaBio Capital Partners helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry, with over 18,000 readers.
More information is available at www.ChinaBioLLC.com.
About BioBay
BioBay is located in Dushu Lake Higher Education Town of Suzhou Industrial Park (SIP). Suzhou Industrial Park (SIP), the largest cooperation program between China and Singapore, is committed to building a globally competitive high-tech industrial park. BioBay is a key driver for innovation and a key focus of growth at SIP, and is a leader in the development of bio and nanotechnology throughout China.
BioBay has more than 240 high-tech companies focusing on biotech, pharmaceutical, diagnostics, medical device, CRO, nanotech, and is committed to building a dynamic and interactive innovation cluster for talents and experts.
For more information, please visit: www.BioBay.com.cn.